Phase 2 Study of Glycopyrronium Bromide for COPD

This is an 8 week, placebo controlled trial to test the efficacy and safety of CHF 5259 (glycopyrronium bromide).

Subjects must be at least 40 years old and must have been diagnosed with COPD for at least 1 year. Subjects must also be on regular COPD therapy.

Subjects may receive up to $825 for their participation in the study.

Share